Skip Navigation


Brain Advance Access originally published online on June 16, 2008
Brain 2008 131(7):1684-1685; doi:10.1093/brain/awn131
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
131/7/1684    most recent
awn131v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lindstrom, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindstrom, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Scientific Commentary

‘Seronegative’ myasthenia gravis is no longer seronegative

The first 10% of the full text of this article appears below.

High-affinity IgG autoantibodies to muscle nicotinic acetylcholine receptors (AChRs) were discovered to cause myasthenia gravis (MG) and its animal model more than 30 years ago (Patrick and Lindstrom, 1973Go; Lindstrom et al., 1976aGo, b; Vincent et al., 2006Go), and the antigenic structure of muscle AChRs is still being actively investigated (Kalamida et al., 2007Go; Lindstrom et al., 2008Go). Immune precipitation of AChRs tagged in their . . . [Full Text of this Article]

Jon Lindstrom

Department of Neuroscience, Medical School of the University of Pennsylvania, Pennsylvania, PA, USA

E-mail: jslkk@mail.med.upenn.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?